Max Healthcare Institute Limited announced its unaudited consolidated financial results for the quarter and half-year ended September 30, 2025. The results showcase a revenue from operations of ₹213,547 lakhs for the quarter. The Board of Directors approved the results on November 14, 2025, with S.R. Batliboi & Co. LLP issuing an unmodified report.
Financial Performance Highlights
For the quarter ended September 30, 2025, Max Healthcare reported:
- Revenue from operations: ₹213,547 lakhs
- Total Income: ₹216,837 lakhs
- Profit before tax: ₹44,603 lakhs
- Profit for the period: ₹49,130 lakhs
The earnings per equity share (EPS) for the quarter are:
- Basic: ₹5.05
- Diluted: ₹5.02
Balance Sheet Summary
Key figures from the consolidated balance sheet as of September 30, 2025:
- Total Equity: ₹10,05,241 lakhs
- Total Assets: ₹16,28,098 lakhs
Additional Key Points
The merger of Crosslay Remedies Limited (CRL) with Jaypee Healthcare Limited (JHL) was approved by NCLT with an appointed date of October 5, 2024. This resulted in a reversal of current tax and recognition of a net deferred tax credit.
As of September 30, 2025, 86,97,585 stock options are outstanding under the Employee Stock Option Plan 2022.
Standalone Financial Results
Max Healthcare also released its standalone financial results. Key highlights include:
- Revenue from operations: ₹73,662 lakhs
- Total Income: ₹78,405 lakhs
- Profit before tax: ₹21,566 lakhs
- Profit for the period: ₹16,042 lakhs
The basic EPS stood at ₹1.65, while diluted EPS was ₹1.64.
Source: BSE